Local News
New Merck pill available soon to treat COVID
Miami, Florida – The drugmaker Merck is seeking emergency use authorization for the pill known as Molnupiravir.
A new breakthrough pill for treating people with Covid that was tested in South Florida may be available in a couple of months.
In clinical trials, the pill cut in half your chances of being hospitalized or dying if you contracted Covid, according to the company.
“It sounds miraculous if there are no side effects,“ said David Light who lives in South Florida.
A part of the clinical trials for the new pill was conducted at research centers in Miami, Hialeah, and Hallandale Beach.
At this time, if you get a bad case of Covid, your treatment options are Monoclonal Antibodies, which is an infusion for people at high risk of hospitalization.
Remdesivir is another therapy is the drug, which is an antiviral given intravenously for people who are hospitalized with Covid.
According to the doctor of pharmacy Miles Gilman “The new drug is designed to interrupt the genetic system.”
If Merck gets emergency approval for the pill, the FDA will issue guidelines on who should get it and when Gilman said.
-
Local News2 weeks ago
Police in Coral Springs are looking into a threat made on social media against Sawgrass Springs Middle School
-
Local News2 weeks ago
On its route to South Florida, Brightline plans to add a new stop
-
Local News2 weeks ago
A man gets an encore performance in jail after serenading police with NWA’s greatest hits in the station parking lot
-
Local News2 weeks ago
What Coral Springs and Coconut Creek have to offer for St. Patrick’s Day Irish Culture Celebrations
-
Local News2 weeks ago
The annual Egg Hunt in Coral Springs is back, ringing festive fun for kids
-
Local News7 days ago
A brand-new farm-to-table restaurant is coming to Coral Springs’ new Cornerstone development
-
Local News1 week ago
Fat Boyz Barbecue has reopened at a new location in Coral Springs
-
Local News1 week ago
Coral Springs athletes compete in BCAA All-Star game
Leave a Reply